248 related articles for article (PubMed ID: 18097016)
1. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition.
Hallett WH; Ames E; Motarjemi M; Barao I; Shanker A; Tamang DL; Sayers TJ; Hudig D; Murphy WJ
J Immunol; 2008 Jan; 180(1):163-70. PubMed ID: 18097016
[TBL] [Abstract][Full Text] [Related]
2. Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition.
Ames E; Hallett WH; Murphy WJ
Clin Exp Immunol; 2009 Mar; 155(3):504-13. PubMed ID: 19220837
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity.
Lundqvist A; Abrams SI; Schrump DS; Alvarez G; Suffredini D; Berg M; Childs R
Cancer Res; 2006 Jul; 66(14):7317-25. PubMed ID: 16849582
[TBL] [Abstract][Full Text] [Related]
4. Effects of bortezomib in sensitizing human prostate cancer cell lines to NK-mediated cytotoxicity.
Hu W; Zheng RR; Cui HX; Yue D; Wang Y; Jiang YH
Asian J Androl; 2012 Sep; 14(5):695-702. PubMed ID: 22902909
[TBL] [Abstract][Full Text] [Related]
5. Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade).
Schumacher LY; Vo DD; Garban HJ; Comin-Anduix B; Owens SK; Dissette VB; Glaspy JA; McBride WH; Bonavida B; Economou JS; Ribas A
J Immunol; 2006 Apr; 176(8):4757-65. PubMed ID: 16585569
[TBL] [Abstract][Full Text] [Related]
6. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
Feng X; Yan J; Wang Y; Zierath JR; Nordenskjöld M; Henter JI; Fadeel B; Zheng C
Mol Immunol; 2010 Aug; 47(14):2388-96. PubMed ID: 20542572
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells.
Lundqvist A; Yokoyama H; Smith A; Berg M; Childs R
Blood; 2009 Jun; 113(24):6120-7. PubMed ID: 19202127
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib and IL-12 produce synergetic anti-multiple myeloma effects with reduced toxicity to natural killer cells.
Wang X; Feng X; Wang J; Shao N; Ji C; Ma D; Henter JI; Fadeel B; Zheng C
Anticancer Drugs; 2014 Mar; 25(3):282-8. PubMed ID: 24300915
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.
Brooks AD; Jacobsen KM; Li W; Shanker A; Sayers TJ
Mol Cancer Res; 2010 May; 8(5):729-38. PubMed ID: 20442297
[TBL] [Abstract][Full Text] [Related]
10. A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells.
Sarhan D; Wennerberg E; D'Arcy P; Gurajada D; Linder S; Lundqvist A
Cancer Immunol Immunother; 2013 Aug; 62(8):1359-68. PubMed ID: 23689729
[TBL] [Abstract][Full Text] [Related]
11. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells.
Berg M; Lundqvist A; McCoy P; Samsel L; Fan Y; Tawab A; Childs R
Cytotherapy; 2009; 11(3):341-55. PubMed ID: 19308771
[TBL] [Abstract][Full Text] [Related]
12. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.
Sayers TJ; Brooks AD; Koh CY; Ma W; Seki N; Raziuddin A; Blazar BR; Zhang X; Elliott PJ; Murphy WJ
Blood; 2003 Jul; 102(1):303-10. PubMed ID: 12637321
[TBL] [Abstract][Full Text] [Related]
13. [Proteasome inhibitor].
Yamamura M; Hirai T; Yamaguchi Y
Nihon Rinsho; 2010 Jun; 68(6):1079-84. PubMed ID: 20535959
[TBL] [Abstract][Full Text] [Related]
14. Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy.
Sayers TJ; Murphy WJ
Cancer Immunol Immunother; 2006 Jan; 55(1):76-84. PubMed ID: 15864587
[TBL] [Abstract][Full Text] [Related]
15. Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.
Shanker A; Brooks AD; Tristan CA; Wine JW; Elliott PJ; Yagita H; Takeda K; Smyth MJ; Murphy WJ; Sayers TJ
J Natl Cancer Inst; 2008 May; 100(9):649-62. PubMed ID: 18445820
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis.
Saulle E; Petronelli A; Pasquini L; Petrucci E; Mariani G; Biffoni M; Ferretti G; Scambia G; Benedetti-Panici P; Cognetti F; Humphreys R; Peschle C; Testa U
Apoptosis; 2007 Apr; 12(4):635-55. PubMed ID: 17252198
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection.
Iwata S; Yano S; Ito Y; Ushijima Y; Gotoh K; Kawada J; Fujiwara S; Sugimoto K; Isobe Y; Nishiyama Y; Kimura H
Int J Cancer; 2011 Nov; 129(9):2263-73. PubMed ID: 21170988
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region.
Kandasamy K; Kraft AS
Mol Cancer Ther; 2008 May; 7(5):1091-100. PubMed ID: 18483298
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells.
Baritaki S; Suzuki E; Umezawa K; Spandidos DA; Berenson J; Daniels TR; Penichet ML; Jazirehi AR; Palladino M; Bonavida B
J Immunol; 2008 May; 180(9):6199-210. PubMed ID: 18424742
[TBL] [Abstract][Full Text] [Related]
20. TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.
Voortman J; Resende TP; Abou El Hassan MA; Giaccone G; Kruyt FA
Mol Cancer Ther; 2007 Jul; 6(7):2103-12. PubMed ID: 17620439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
